BTAI (STOCKS)
BioXcel Therapeutics, Inc. Common Stock
$1.160000
+0.020000 (+1.75%)
Prev close: $1.140000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Vimal D. Mehta
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $35.97M
- Employees
- 37
- P/E (TTM)
- -0.18
- P/B (TTM)
- -0.29
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
7
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.54 | $-0.84 | +0.3001 | +35.72% |
|
Dec 2025 (Q4)
|
$-0.58 | $-0.77 | +0.1850 | +24.18% |
|
Sep 2025 (Q3)
|
$-2.18 | $-1.20 | -0.9789 | -81.50% |
|
Jun 2025 (Q2)
|
$-2.45 | $-1.89 | -0.5569 | -29.42% |
Financial Statements
| Revenues | $680.00K |
| Benefits Costs and Expenses | $56.00M |
| Cost Of Revenue | $433.00K |
| Costs And Expenses | $51.27M |
| Gross Profit | $247.00K |
| Operating Expenses | $50.83M |
| Selling, General, and Administrative Expenses | $21.99M |
| Research and Development | $28.65M |
| Operating Income/Loss | -$50.59M |
| Income/Loss From Continuing Operations After Tax | -$75.33M |
| Income/Loss From Continuing Operations Before Tax | -$58.65M |
| Net Income/Loss | -$75.33M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$75.33M |
| Net Income/Loss Available To Common Stockholders, Basic | -$75.33M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.52 |
| Diluted Earnings Per Share | -$4.52 |
| Basic Average Shares | 48,826,000 |
| Diluted Average Shares | 48,826,000 |
| Assets | $34.03M |
| Current Assets | $33.91M |
| Accounts Receivable | $216.00K |
| Inventory | $500.00K |
| Other Current Assets | $33.19M |
| Noncurrent Assets | $117.00K |
| Fixed Assets | $117.00K |
| Liabilities | $139.57M |
| Current Liabilities | $54.99M |
| Accounts Payable | $16.25M |
| Wages | $11.00K |
| Other Current Liabilities | $38.74M |
| Noncurrent Liabilities | $84.57M |
| Long-term Debt | $100.29M |
| Equity | -$105.54M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$105.54M |
| Liabilities And Equity | $34.03M |
| Net Cash Flow From Operating Activities | -$57.38M |
| Net Cash Flow From Operating Activities, Continuing | -$57.38M |
| Net Cash Flow From Investing Activities | $13.83M |
| Net Cash Flow From Investing Activities, Continuing | $13.83M |
| Net Cash Flow From Financing Activities | $43.55M |
| Net Cash Flow From Financing Activities, Continuing | $43.55M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$75.33M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$75.33M |
| Other Comprehensive Income/Loss | $0.00 |